Hansa Medical appoints Henk Doude van Troostwijk as Vice President, Commercial Operations

Hansa Medical AB (publ) announced today the appointment of Henk Doude van
Troostwijk as Vice President, Commercial Operations to strengthen its management
team.
Henk´s key focus will be on the company’s commercial assessments of its lead
project IdeS, including market access, pricing and re-imbursement aspects. IdeS
is now in Phase II clinical development focused on kidney transplantation in
sensitized patients.

“We are very excited that Henk will engage in Hansa Medical, as we now start to
prepare our commercialization strategy for IdeS”, said Göran Arvidson, President
and CEO of Hansa Medical.

Henk has significant management experience in sales and marketing from the areas
of transplantation and orphan drugs.  Lately, Henk has served as Business Unit
Director Oncology and Transplantation at Genzyme and most recently as General
Manager of European Commercial Operations and Emerging Markets at Raptor
Pharmaceuticals, an orphan disease focused global biopharma company based in the
US. Henk holds an MBA from Henley Management College at the University of
Reading, UK

Besides Henk, the management team of Hansa Medical consists of:
Göran Arvidson                          President and CEO
Christian Kjellman                      Senior Vice President, Research and
Development
Emanuel Björne                         Vice President, Business Development and
Investor Relations
Steven Glazer                            Vice President, Chief Medical Officer
Eva-Maria Joed                          Vice President, Chief Financial Officer
Lena Winstedt                            Vice President, Project Management
For further information, please contact:
Hansa Medical AB
Göran Arvidson, CEO
Mobile: 46 70-633 30 42
E-mail: goran.arvidson@hansamedical.com
www.hansamedical.com
About Hansa Medical AB
Hansa Medical is a biopharmaceutical company focusing on novel immunomodulatory
enzymes. The lead project IdeS is an antibody-degrading enzyme in clinical
development, with potential use in transplantation and rare autoimmune diseases.
Additional projects focus on development of new antibody modulating enzymes, as
well as HBP, a diagnostic biomarker for prediction of severe sepsis at emergency
departments that is already introduced on the market. The company is based in
Lund, Sweden. Hansa Medical’s share (ticker: HMED) is listed on Nasdaq
Stockholm.